Telegram Group & Telegram Channel
中国生物制药:盐酸安罗替尼获批用于软组织肉瘤一线治疗

盐酸安罗替尼胶囊联合化疗方案获国家药监局批准,用于局部晚期或转移性软组织肉瘤患者的一线治疗。这是该药物在中国获批的第九个适应症,也是全球首个获批的联合化疗方案用于此类疾病一线治疗。此前,安罗替尼单药已被推荐用于二线治疗,并为唯一I级推荐的靶向药物。

媒体报道
中国生物制药:盐酸安罗替尼获批用于软组织肉瘤一线治疗 第一财经
第9个适应症!安罗替尼获批联合化疗一线治疗软组织肉瘤 医药魔方
安罗替尼联合化疗一线治疗软组织肉瘤适应症获批上市 医药魔方

#热门话题



tg-me.com/readhub_cn/273689
Create:
Last Update:

中国生物制药:盐酸安罗替尼获批用于软组织肉瘤一线治疗

盐酸安罗替尼胶囊联合化疗方案获国家药监局批准,用于局部晚期或转移性软组织肉瘤患者的一线治疗。这是该药物在中国获批的第九个适应症,也是全球首个获批的联合化疗方案用于此类疾病一线治疗。此前,安罗替尼单药已被推荐用于二线治疗,并为唯一I级推荐的靶向药物。

媒体报道
中国生物制药:盐酸安罗替尼获批用于软组织肉瘤一线治疗 第一财经
第9个适应症!安罗替尼获批联合化疗一线治疗软组织肉瘤 医药魔方
安罗替尼联合化疗一线治疗软组织肉瘤适应症获批上市 医药魔方

#热门话题

BY Readhub


Warning: Undefined variable $i in /var/www/tg-me/post.php on line 283

Share with your friend now:
tg-me.com/readhub_cn/273689

View MORE
Open in Telegram


Readhub Telegram | DID YOU KNOW?

Date: |

A Telegram spokesman declined to comment on the bond issue or the amount of the debt the company has due. The spokesman said Telegram’s equipment and bandwidth costs are growing because it has consistently posted more than 40% year-to-year growth in users.

Importantly, that investor viewpoint is not new. It cycles in when conditions are right (and vice versa). It also brings the ineffective warnings of an overpriced market with it.Looking toward a good 2022 stock market, there is no apparent reason to expect these issues to change.

Readhub from us


Telegram Readhub
FROM USA